Simultaneous Release of Aflibercept and Dexamethasone from an Ocular Drug Delivery System

Rudeen, Kayla M; Liu, Wenqiang; Mieler, William F.; Kang-Mieler, Jennifer J.

doi:10.1080/02713683.2022.2053166

Cited by 12 publications

(10 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They are capable of increasing drug residence time and sustaining drug delivery to biomechanically modulate ocular wound healing. Many drugs with the potential for preventing ocular fibrosis have been tested in hydrogels for sustained release, including 5-FU, MMC, ranibizumab, and dexamethasone [ 115 , 188 , 189 , 190 , 191 ]. Hydrogels can provide specific mechanical signaling cues by acting as scaffolds for the infiltrating restorative cells, which makes them a promising approach for spatiotemporal control of ocular fibrosis.…”

Section: Novel Delivery Techniques and Biomaterialsmentioning

confidence: 99%

Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery

et al. 2023

View full text Add to dashboard Cite

Conjunctival fibrosis remains the major impediment to the success of glaucoma filtration surgery. Anti-metabolites remain the gold standard for mitigating post-surgical fibrosis, but they are associated with high complication rates and surgical failure rates. Establishing a more targeted approach to attenuate conjunctival fibrosis may revolutionize the surgical approach to glaucoma. A new strategy is needed to prevent progressive tissue remodeling and formation of a fibrotic scar, subsequently increasing surgical success and reducing the prevalence of glaucoma-related vision loss. Advancements in our understanding of molecular signaling and biomechanical cues in the conjunctival tissue architecture are broadening the horizon for new therapies and biomaterials for the mitigation of fibrosis. This review aims to highlight the strategies and current state of promising future approaches for targeting fibrosis in glaucoma filtration surgery.

show abstract

Section: Novel Delivery Techniques and Biomaterialsmentioning

confidence: 99%

Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery

et al. 2023

View full text Add to dashboard Cite

show abstract

“…This approach has the potential to deliver a sustained release of the encapsulated protein for a duration of over 2 months ex vivo and effectively circumvent the scleral barrier. The co-administration of dexamethasone with anti-VEGF agents such as aflibercept and bevacizumab as polymeric NPs has been demonstrated to exhibit a prolonged release profile, a potent anti-angiogenic effect [ 150 , 156 ]. The studies discussed provide a potential avenue for a promising therapeutic approach in treating CNV through the combination of different biodegradable formulations and co-administration of two drugs in a single injection.…”

Section: Application Of Different Biodegradable Ocular Drug Delivery ...mentioning

confidence: 99%

Updates on Biodegradable Formulations for Ocular Drug Delivery

Tsung

Chen

2023

Pharmaceutics

View full text Add to dashboard Cite

The complex nature of the ocular drug delivery barrier presents a significant challenge to the effective administration of drugs, resulting in poor therapeutic outcomes. To address this issue, it is essential to investigate new drugs and alternative delivery routes and vehicles. One promising approach is the use of biodegradable formulations to develop potential ocular drug delivery technologies. These include hydrogels, biodegradable microneedles, implants, and polymeric nanocarriers such as liposomes, nanoparticles, nanosuspensions, nanomicelles, and nanoemulsions. The research in these areas is rapidly growing. In this review, we provide an overview of recent updates in biodegradable formulations for ocular drug delivery over the past decade. Additionally, we examine the clinical use of different biodegradable formulations in various ocular diseases. The aim of this review is to gain a deeper understanding of potential future trends in biodegradable ocular drug delivery systems and to raise awareness of their potential for practical clinical application as a means of providing new treatment options for ocular diseases.

show abstract

“…81 Most recently, a combination composite DDS containing both aflibercept and dexamethasoneloaded microparticles has been investigated, showing that additional therapeutic effect can be achieved without influencing the release kinetics of the 2 agents. 82 FIGURE 2. The ranibizumab refillable port delivery system.…”

Section: Composite Drug Delivery Systemmentioning

confidence: 99%

“…In addition, in vivo efficacy has been demonstrated in a laser-induced CNV rat model, where a single intravitreal injection of the aflibercept microsphere-hydrogel DDS was able to reduce lesion size through 6 months 81 . Most recently, a combination composite DDS containing both aflibercept and dexamethasone-loaded microparticles has been investigated, showing that additional therapeutic effect can be achieved without influencing the release kinetics of the 2 agents 82 …”

Section: Intravitreal Delivery Systemmentioning

confidence: 99%

Novel Drug Delivery Methods and Approaches for the Treatment of Retinal Diseases

Ham¹,

Mehta

Kang-Mieler

et al. 2023

Asia-Pacific Journal of Ophthalmology

Self Cite

View full text Add to dashboard Cite

This review discusses emerging approaches to ocular drug delivery for retinal diseases. Intravitreal injections have proven to be an effective, safe, and commonly used drug delivery method. However, the optimal management of chronic retinal diseases requires frequent intravitreal injections over extended periods of time. Although this can be achieved in a clinical trial environment, it is difficult to replicate in routine clinical practice. In addition, frequent treatment increases the risk of complications, incurs more costs, and increases the treatment burden for patients and caregivers. Given the aging global population and diabetes pandemic, there is an urgent need for drug delivery methods that support more durable retinal therapy while maintaining the efficacy and safety of currently available intravitreal therapies. Several innovative drug delivery methods are currently being investigated. These include sustained-release implants and depots using prodrugs, microparticles, and hydrogels, surgically implanted reservoirs, gene therapy via submacular injections or suprachoroidal injections, as well as topical and systemic therapies.

show abstract

Simultaneous Release of Aflibercept and Dexamethasone from an Ocular Drug Delivery System

Cited by 12 publications

References 51 publications

Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery

Novel Therapies for the Prevention of Fibrosis in Glaucoma Filtration Surgery

Updates on Biodegradable Formulations for Ocular Drug Delivery

Novel Drug Delivery Methods and Approaches for the Treatment of Retinal Diseases

Contact Info

Product

Resources

About